HYPR · Hyperfine, Inc.

Hyperfine reported strong first quarter 2026 results, with revenue of $3.90 million, an 83% increase year-over-year, driven by 10 commercial Swoop system sales compared to six in the prior year. Gross margin expanded to 51% from 41%, reflecting improved product mix and cost efficiencies. Operating expenses decreased 11% to $10.54 million, primarily due to a 24% reduction in R&D spending to $3.85 million, while SG&A remained flat at $6.69 million. Net loss narrowed to $8.62 million ($0.09 per share) from $9.42 million ($0.12 per share) in Q1 2025. The company maintained its full-year 2026 guidance, expecting revenue of $20-22 million (55% growth at midpoint) and cash burn of $26-28 million (10% decline at midpoint). Management highlighted strong execution, international regulatory clearances (CE Mark and UKCA), and clinical data supporting portable brain MRI adoption. The balance sheet was bolstered by $15.0 million in debt financing, extending cash runway into 2028. Key operational achievements include enrollment progress in the Contrast PMR study, positive NEURO-PMR results, and launch activities in India.